vs

Side-by-side financial comparison of Empire State Realty OP, L.P. (ESBA) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

MYRIAD GENETICS INC is the larger business by last-quarter revenue ($209.8M vs $199.2M, roughly 1.1× Empire State Realty OP, L.P.). On growth, Empire State Realty OP, L.P. posted the faster year-over-year revenue change (0.8% vs -0.4%). Over the past eight quarters, Empire State Realty OP, L.P.'s revenue compounded faster (4.9% CAGR vs 1.9%).

Empire State Realty OP, L.P. is a real estate operating partnership focused on owning, managing, and leasing premium commercial and retail properties primarily in the New York City metropolitan area. Its portfolio includes iconic landmarks like the Empire State Building, serving corporate tenants, retail brands and tourism-related business segments.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

ESBA vs MYGN — Head-to-Head

Bigger by revenue
MYGN
MYGN
1.1× larger
MYGN
$209.8M
$199.2M
ESBA
Growing faster (revenue YoY)
ESBA
ESBA
+1.2% gap
ESBA
0.8%
-0.4%
MYGN
Faster 2-yr revenue CAGR
ESBA
ESBA
Annualised
ESBA
4.9%
1.9%
MYGN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESBA
ESBA
MYGN
MYGN
Revenue
$199.2M
$209.8M
Net Profit
$32.2M
Gross Margin
70.0%
Operating Margin
17.8%
-2.7%
Net Margin
16.1%
Revenue YoY
0.8%
-0.4%
Net Profit YoY
71.2%
EPS (diluted)
$0.11
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESBA
ESBA
MYGN
MYGN
Q4 25
$199.2M
$209.8M
Q3 25
$197.7M
$205.7M
Q2 25
$191.3M
$213.1M
Q1 25
$180.1M
$195.9M
Q4 24
$197.6M
$210.6M
Q3 24
$199.6M
$213.3M
Q2 24
$189.5M
$211.5M
Q1 24
$181.2M
$202.2M
Net Profit
ESBA
ESBA
MYGN
MYGN
Q4 25
$32.2M
Q3 25
$13.6M
$-27.4M
Q2 25
$11.4M
$-330.5M
Q1 25
$15.8M
$-100.0K
Q4 24
$18.8M
Q3 24
$22.8M
$-22.1M
Q2 24
$28.6M
$-36.7M
Q1 24
$10.2M
$-26.0M
Gross Margin
ESBA
ESBA
MYGN
MYGN
Q4 25
70.0%
Q3 25
69.9%
Q2 25
71.2%
Q1 25
68.5%
Q4 24
71.7%
Q3 24
70.2%
Q2 24
69.6%
Q1 24
68.1%
Operating Margin
ESBA
ESBA
MYGN
MYGN
Q4 25
17.8%
-2.7%
Q3 25
19.9%
-11.3%
Q2 25
18.4%
-154.5%
Q1 25
14.3%
-14.8%
Q4 24
21.7%
-18.6%
Q3 24
22.7%
-9.4%
Q2 24
20.8%
-17.3%
Q1 24
17.1%
-13.8%
Net Margin
ESBA
ESBA
MYGN
MYGN
Q4 25
16.1%
Q3 25
6.9%
-13.3%
Q2 25
6.0%
-155.1%
Q1 25
8.8%
-0.1%
Q4 24
9.5%
Q3 24
11.4%
-10.4%
Q2 24
15.1%
-17.4%
Q1 24
5.6%
-12.9%
EPS (diluted)
ESBA
ESBA
MYGN
MYGN
Q4 25
$0.11
$-0.09
Q3 25
$0.05
$-0.29
Q2 25
$0.04
$-3.57
Q1 25
$0.05
$0.00
Q4 24
$0.07
$-0.47
Q3 24
$0.08
$-0.24
Q2 24
$0.10
$-0.41
Q1 24
$0.03
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESBA
ESBA
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$132.7M
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$368.0M
Total Assets
$4.5B
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESBA
ESBA
MYGN
MYGN
Q4 25
$132.7M
$149.6M
Q3 25
$154.1M
$145.4M
Q2 25
$94.6M
$74.4M
Q1 25
$187.8M
$91.8M
Q4 24
$385.5M
$102.4M
Q3 24
$421.9M
$99.9M
Q2 24
$535.5M
$97.3M
Q1 24
$333.6M
$104.3M
Total Debt
ESBA
ESBA
MYGN
MYGN
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESBA
ESBA
MYGN
MYGN
Q4 25
$368.0M
Q3 25
$372.8M
Q2 25
$388.1M
Q1 25
$704.9M
Q4 24
$701.1M
Q3 24
$731.7M
Q2 24
$740.5M
Q1 24
$760.0M
Total Assets
ESBA
ESBA
MYGN
MYGN
Q4 25
$4.5B
$706.6M
Q3 25
$4.1B
$728.1M
Q2 25
$4.1B
$677.3M
Q1 25
$4.1B
$1.0B
Q4 24
$4.5B
$1.0B
Q3 24
$4.4B
$1.1B
Q2 24
$4.4B
$1.1B
Q1 24
$4.2B
$1.1B
Debt / Equity
ESBA
ESBA
MYGN
MYGN
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESBA
ESBA
MYGN
MYGN
Operating Cash FlowLast quarter
$249.1M
$10.6M
Free Cash FlowOCF − Capex
$50.6M
FCF MarginFCF / Revenue
25.4%
Capex IntensityCapex / Revenue
99.6%
Cash ConversionOCF / Net Profit
7.74×
TTM Free Cash FlowTrailing 4 quarters
$109.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESBA
ESBA
MYGN
MYGN
Q4 25
$249.1M
$10.6M
Q3 25
$105.3M
$21.1M
Q2 25
$26.7M
$-13.6M
Q1 25
$83.1M
$-16.3M
Q4 24
$260.9M
$6.6M
Q3 24
$102.8M
$700.0K
Q2 24
$37.1M
$2.6M
Q1 24
$70.9M
$-18.6M
Free Cash Flow
ESBA
ESBA
MYGN
MYGN
Q4 25
$50.6M
Q3 25
$72.8M
Q2 25
$-55.1M
Q1 25
$41.1M
Q4 24
$88.0M
Q3 24
$-65.1M
Q2 24
$19.5M
Q1 24
$23.2M
FCF Margin
ESBA
ESBA
MYGN
MYGN
Q4 25
25.4%
Q3 25
36.8%
Q2 25
-28.8%
Q1 25
22.8%
Q4 24
44.5%
Q3 24
-32.6%
Q2 24
10.3%
Q1 24
12.8%
Capex Intensity
ESBA
ESBA
MYGN
MYGN
Q4 25
99.6%
Q3 25
16.5%
Q2 25
42.8%
Q1 25
23.4%
Q4 24
87.5%
Q3 24
84.1%
Q2 24
9.3%
Q1 24
26.3%
Cash Conversion
ESBA
ESBA
MYGN
MYGN
Q4 25
7.74×
Q3 25
7.72×
Q2 25
2.35×
Q1 25
5.27×
Q4 24
13.88×
Q3 24
4.51×
Q2 24
1.30×
Q1 24
6.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESBA
ESBA

Real Estate Segment$163.8M82%
Observatory Segment$35.2M18%

MYGN
MYGN

Segment breakdown not available.

Related Comparisons